Start-Up Magazine Emerging Company Profile

Phrixus Pharmaceuticals, Inc. aims to repurpose a compound that may be able to boost the blood-pumping capacity of damaged hearts. Carmeseal was originally developed in the 1950s by BASF as a surfactant called poloxamer-188. If results seen in several animal cardiovascular models can be reproduced in humans, Phrixus’s compound could become an emergency rm treatment for acute decompensated hear failure.

read more

Share